187 related articles for article (PubMed ID: 28277065)
1. Gene of the issue: RUNX1 mutations and inherited bleeding.
Morgan NV; Daly ME
Platelets; 2017 Mar; 28(2):208-210. PubMed ID: 28277065
[No Abstract] [Full Text] [Related]
2. Bone Marrow Morphology Associated With Germline
Chisholm KM; Denton C; Keel S; Geddis AE; Xu M; Appel BE; Cantor AB; Fleming MD; Shimamura A
Pediatr Dev Pathol; 2019; 22(4):315-328. PubMed ID: 30600763
[TBL] [Abstract][Full Text] [Related]
3. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
[TBL] [Abstract][Full Text] [Related]
4. GENYOi005-A: An induced pluripotent stem cells (iPSCs) line generated from a patient with Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) carrying a p.Thr196Ala variant.
Lamolda M; Montes R; Simón I; Perales S; Martínez-Navajas G; Lopez-Onieva L; Ríos-Pelegrina R; Del Moral RG; Griñan-Lison C; Marchal JA; Lozano ML; Ramos-Mejia V; Rivera J; Bastida JM; Real PJ
Stem Cell Res; 2019 Dec; 41():101603. PubMed ID: 31698193
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan.
Yoshimi A; Toya T; Nannya Y; Takaoka K; Kirito K; Ito E; Nakajima H; Hayashi Y; Takahashi T; Moriya-Saito A; Suzuki K; Harada H; Komatsu N; Usuki K; Ichikawa M; Kurokawa M
Ann Oncol; 2016 May; 27(5):887-95. PubMed ID: 26884589
[TBL] [Abstract][Full Text] [Related]
6. Myeloid neoplasms with germ line RUNX1 mutation.
Hayashi Y; Harada Y; Huang G; Harada H
Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
[TBL] [Abstract][Full Text] [Related]
7. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders.
Latger-Cannard V; Philippe C; Bouquet A; Baccini V; Alessi MC; Ankri A; Bauters A; Bayart S; Cornillet-Lefebvre P; Daliphard S; Mozziconacci MJ; Renneville A; Ballerini P; Leverger G; Sobol H; Jonveaux P; Preudhomme C; Nurden P; Lecompte T; Favier R
Orphanet J Rare Dis; 2016 Apr; 11():49. PubMed ID: 27112265
[TBL] [Abstract][Full Text] [Related]
8. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).
Schlegelberger B; Heller PG
Semin Hematol; 2017 Apr; 54(2):75-80. PubMed ID: 28637620
[TBL] [Abstract][Full Text] [Related]
9. Platelet CD34 expression and α/δ-granule abnormalities in
Marneth AE; van Heerde WL; Hebeda KM; Laros-van Gorkom BA; Barteling W; Willemsen B; de Graaf AO; Simons A; Jansen JH; Preijers F; Jongmans MC; van der Reijden BA
Blood; 2017 Mar; 129(12):1733-1736. PubMed ID: 28096094
[No Abstract] [Full Text] [Related]
10. Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis.
Iizuka H; Kagoya Y; Kataoka K; Yoshimi A; Miyauchi M; Taoka K; Kumano K; Yamamoto T; Hotta A; Arai S; Kurokawa M
Exp Hematol; 2015 Oct; 43(10):849-57. PubMed ID: 26021490
[TBL] [Abstract][Full Text] [Related]
11. A novel RUNX1 exon 3 - 7 deletion causing a familial platelet disorder.
Almazni I; Chudakou P; Dawson-Meadows A; Downes K; Freson K; Mason J; Page P; Reay K; Myers B; Morgan NV;
Platelets; 2022 Feb; 33(2):320-323. PubMed ID: 33616470
[TBL] [Abstract][Full Text] [Related]
12. Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies.
Decker M; Lammens T; Ferster A; Erlacher M; Yoshimi A; Niemeyer CM; Ernst MPT; Raaijmakers MHGP; Duployez N; Flaum A; Steinemann D; Schlegelberger B; Illig T; Ripperger T
Leukemia; 2021 Nov; 35(11):3304-3308. PubMed ID: 33692461
[No Abstract] [Full Text] [Related]
13. Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.
Krutein MC; Hart MR; Anderson DJ; Jeffery J; Kotini AG; Dai J; Chien S; DelPriore M; Borst S; Maguire JA; French DL; Gadue P; Papapetrou EP; Keel SB; Becker PS; Horwitz MS
Blood Adv; 2021 Feb; 5(3):687-699. PubMed ID: 33560381
[TBL] [Abstract][Full Text] [Related]
14. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.
Antony-Debré I; Bluteau D; Itzykson R; Baccini V; Renneville A; Boehlen F; Morabito M; Droin N; Deswarte C; Chang Y; Leverger G; Solary E; Vainchenker W; Favier R; Raslova H
Blood; 2012 Sep; 120(13):2719-22. PubMed ID: 22677128
[TBL] [Abstract][Full Text] [Related]
15. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.
Manchev VT; Bouzid H; Antony-Debré I; Leite B; Meurice G; Droin N; Prebet T; Costello RT; Vainchenker W; Plo I; Diop M; Macintyre E; Asnafi V; Favier R; Baccini V; Raslova H
J Cell Mol Med; 2017 Jun; 21(6):1237-1242. PubMed ID: 27997762
[TBL] [Abstract][Full Text] [Related]
16. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome.
Jongmans MC; Kuiper RP; Carmichael CL; Wilkins EJ; Dors N; Carmagnac A; Schouten-van Meeteren AY; Li X; Stankovic M; Kamping E; Bengtsson H; Schoenmakers EF; van Kessel AG; Hoogerbrugge PM; Hahn CN; Brons PP; Scott HS; Hoogerbrugge N
Leukemia; 2010 Jan; 24(1):242-6. PubMed ID: 19946261
[No Abstract] [Full Text] [Related]
17. Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.
Sakurai M; Kunimoto H; Watanabe N; Fukuchi Y; Yuasa S; Yamazaki S; Nishimura T; Sadahira K; Fukuda K; Okano H; Nakauchi H; Morita Y; Matsumura I; Kudo K; Ito E; Ebihara Y; Tsuji K; Harada Y; Harada H; Okamoto S; Nakajima H
Leukemia; 2014 Dec; 28(12):2344-54. PubMed ID: 24732596
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia in a child with hereditary thrombocytopenia.
Rheingold SR
Pediatr Blood Cancer; 2007 Jan; 48(1):105-7. PubMed ID: 16276527
[TBL] [Abstract][Full Text] [Related]
19. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
Michaud J; Wu F; Osato M; Cottles GM; Yanagida M; Asou N; Shigesada K; Ito Y; Benson KF; Raskind WH; Rossier C; Antonarakis SE; Israels S; McNicol A; Weiss H; Horwitz M; Scott HS
Blood; 2002 Feb; 99(4):1364-72. PubMed ID: 11830488
[TBL] [Abstract][Full Text] [Related]
20. Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression.
Bluteau D; Glembotsky AC; Raimbault A; Balayn N; Gilles L; Rameau P; Nurden P; Alessi MC; Debili N; Vainchenker W; Heller PG; Favier R; Raslova H
Blood; 2012 Sep; 120(13):2708-18. PubMed ID: 22898599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
